eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
abortion-rights supporters have described the proposal as a "gag rule" and say it would undermine reproductive health care for low-income patients.
.
. it also provides 85 per cent accurate prediction results than current methods.
. may 16, 2018
.
español
.
may 16, 2018
.